Lumicitabine binds RdRP on nucleocapsid

Stable Identifier
R-HSA-9845222
Type
Reaction [binding]
Species
Homo sapiens
Related Species
Human respiratory syncytial virus A
Compartment
cytosol
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Lumicitabine binds RdRP on nucleocapsid
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Lumicitabine (ALS-8176) is an orally administered nucleoside analog targeting the RSV polymerase. Two phase 2 trials showed mixed safety and efficacy results in reducing viral load in patients (DeVincenzo et al., 2015; Oey et al., 2023).
Literature References
PubMed ID Title Journal Year
37467213 Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results

Symons, JA, Chokephaibulkit, K, Oey, A, Smith, PF, Fayon, M, Luciani, K, Witek, J, Stanley, T, Chanda, S, Uppala, R, Fry, J, Huntjens, D, Furuno, K, Bernatoniene, J, McClure, M

PLoS One 2023
26580997 Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

Fathi, H, Symons, JA, Chanda, S, Fry, J, McClure, MW, Beigelman, L, Westland, C, Smith, P, Lambkin-Williams, R, DeVincenzo, JP, Blatt, LM, Zhang, Q

N Engl J Med 2015
Participants
Input
Output
Participates
as an event of
Disease
Authored
Stephan, R  (2023-09-28)
Reviewed
Bergeron, HC  (2023-11-03)
Created
Stephan, R  (2023-09-28)
Cite Us!